Associations Of Genetic Polymorphisms Of Pai-1 And Par-1 With Acute Normal Tissue Toxicity In Rectal Cancer Patients Treated With Pelvic Radiation Therapy

Haishi Zhang,Mengyun Wang,Ting Yan Shi,Lijun Shen,Jinhong Zhu,Menghong Sun,Yun Deng,L. Liang,Guichao Li,Y. Wu,M. Fan,Qingyi Wei,Zhen Zhang

DOI: https://doi.org/10.1016/j.ijrobp.2015.07.1854

2015-01-01

Abstract:To explore whether genetic variants are predictors of radiation-induced injury in rectal cancer, we investigated associations between single nucleotide polymorphisms (SNPs) in plasminogen activator inhibitor type 1 (PAI-1) and protease-activated receptor-1 (PAR-1) and acute radiation toxicity in rectal cancer after pelvic radiation therapy. This study included 356 patients with rectal cancer, who received pelvic radiation therapy. Acute adverse events including dermatitis, incontinence (anal toxicity), hematologic toxicity, diarrhea, and vomiting were scored. The patients were grouped into grade ≥2 and grade 0-1 for analysis of each acute toxicities. Genotyping of six SNPs in PAI-1 and PAR-1 was determined by the TaqMan assay. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Of the 356 patients, 264 (72.5%) had grade ≥2 toxicities and 65 (18.3%) had grade ≥3 toxicities. Variant genotype GG of rs1050955 in PAI-1 was found to be negatively associated with risk of diarrhea and incontinence (p<0.05), while genotype AG and GG of rs2227631 in PAI-1 was associated with an increased risk of incontinence. Genotype CT of PAR-1 rs32934 was associated with an increased risk of total toxicity compared with CC genotype. Our results demonstrated that SNPs in PAI-1 and PAR-1 genes were associated with acute injury in rectal cancer with pelvic irradiation. Specifically, rs2227631 and rs1050955 in PAI-1 were obvious associated with diarrhea and incontinence in patients with rectal cancer, which may be useful biomarkers for predicting acute toxicity in rectal cancer if validated in future studies.